Author:
Lobbous Mina,R. Korf Bruce
Reference126 articles.
1. Huson SM, Harper PS, Compston DAS. Von recklinghausen neurofibromatosisa clinical and population study in south-east Wales. Brain. 1988;111(6):1355-1381. DOI: 10.1093/brain/111.6.1355
2. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service—Evans. American Journal of Medical Genetics Part A—Wiley Online Library. 2010. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.33139 [Accessed: 16 June 2019]
3. Packer RJ et al. Neurofibromatosis clinical trial consortium. Journal of Child Neurology. 2018;33(1):82-91. DOI: 10.1177/0883073817739196
4. Meeting Library. SPRINT: Phase II Study of the MEK 1/2 Inhibitor Selumetinib (AZD6244, ARRY-142886) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN). Available from: https://meetinglibrary.asco.org/record/159508/abstract [Accessed: 24 June 2019]
5. La Rosa S et al. Delivering on the vision of bench to bedside: A rare disease funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors. BioRxiv. 2019:552976. DOI: 10.1101/552976
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献